Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cardiovascular pharmacogenomics: current status, future prospects.

Jeffrey L Anderson1, John F Carlquist, Benjamin D Horne

  • 1Intermountain Heart Collaborative Research Group, LDS Hospital Cardiovascular Department, and University of Utah School of Medicine, Salt Lake City, Utah 84143, USA.

Journal of Cardiovascular Pharmacology and Therapeutics
|March 26, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Target Trial Emulation of Vaccine Effectiveness in 5- to 17-years-olds with Prior SARS-CoV-2 Infection.

Nature communications·2026
Same author

Pilot proteomics study for identifying a pollution exposure signature in firefighters.

Journal of exposure science & environmental epidemiology·2026
Same author

Risk of venous thromboembolism associated with short-term exposure to fine particulate matter (PM<sub>2.5</sub>) and ozone air pollution.

Research and practice in thrombosis and haemostasis·2025
Same author

Age-Related Changes in the Clinical Picture of Long COVID.

Journal of the American Geriatrics Society·2025
Same author

A multi-omics strategy to understand PASC through the RECOVER cohorts: a paradigm for a systems biology approach to the study of chronic conditions.

Frontiers in systems biology·2025
Same author

Intermittent fasting and a no-sugar diet for Long COVID symptoms: a randomized crossover trial.

Scientific reports·2025

Pharmacogenomics uses genetics to predict how individuals respond to cardiovascular drugs, optimizing treatment and reducing side effects. This field is rapidly advancing for clinical use in drug selection and development.

Area of Science:

  • Cardiovascular medicine
  • Pharmacogenomics
  • Genetics

Background:

  • Individual genetic variations significantly influence drug responses.
  • Understanding these variations is key to optimizing cardiovascular drug therapy.
  • Pharmacogenomics aims to tailor drug selection and development for improved patient outcomes.

Purpose of the Study:

  • To explore the role of genetics in cardiovascular drug response variability.
  • To guide cardiovascular drug development and selection for enhanced efficacy and safety.
  • To summarize the current and future clinical potential of pharmacogenomics in cardiology.

Main Methods:

  • Reviewing genetic polymorphisms affecting cardiovascular drug metabolism and pharmacodynamics.
  • Examining drug classes including antiarrhythmics, renin-angiotensin agents, beta-blockers, lipid-lowering, and antithrombotics.

Related Experiment Videos

  • Discussing principles of pharmacogenomics related to drug metabolism (CYP450, phase II enzymes, transporters).

    • Main Results:

    • Genetic variations impact cardiovascular drug efficacy and toxicity.
    • Pharmacogenomic principles are relevant for drug development and clinical practice.
    • Examples include effects on antiarrhythmics, beta-blockers, and antithrombotics.

    Conclusions:

    • Pharmacogenomics offers promising applications for personalized cardiovascular medicine.
    • Challenges in establishing robust pharmacogenetic associations are being addressed.
    • Rapid progress suggests near-future clinical implementation of pharmacogenomics in cardiology.